

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): January 24, 2022

HARVARD BIOSCIENCE, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-33957
(Commission File Number)

04-3306140
(I.R.S. Employer Identification Number)

84 October Hill Road
Holliston, MA 01746
(Address of Principal Executive Offices) (Zip Code)

(508) 893-8999
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	HBIO	The NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01 **Entry into a Material Definitive Agreement.**

Item 5.02 **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 24, 2022, Harvard Bioscience, Inc. (the “Company”) accepted the resignation of Ken Olson for personal reasons from his position as Chief Operating Officer of the Company effective January 31, 2022. Mr. Olson will assist on various projects and in the transition of the Chief Operating Officer role until his departure from the Company on December 31, 2022. Mr. Olson’s resignation was not the result of any disagreement related to any matter involving the Company’s operations, policies or practices.

In connection with Mr. Olson’s departure, on January 26, 2022, the Company and Mr. Olson entered into a Separation Agreement and Release (the “Separation Agreement”) attached hereto as Exhibit 10.1. Under the terms of the Separation Agreement, the Company will, among other things, continue to employ Mr. Olson and pay him his current salary until December 31, 2022 in exchange for his remote assistance on projects and the transition of duties, unless earlier terminated.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 **Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
10.1	Separation Agreement and Release between Harvard Bioscience, Inc. and Ken Olson, dated as of January 26, 2022.
104	Cover Page Interactive Data File (embedded within the XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HARVARD BIOSCIENCE, INC.

Date: January 28, 2022

By: /s/ Michael A. Rossi
Michael A. Rossi
Chief Financial Officer

SEPARATION AGREEMENT AND RELEASE

This Separation Agreement (this “Agreement”), dated as of January 26, 2022 (the “Agreement Date”) is entered into by and between HARVARD BIOSCIENCE, INC. (the “Company”) and KEN OLSON (“Employee,” and, together with the Company, the “Parties”). All capitalized terms not defined herein shall be given the definition as provided in the Parties’ September 18, 2019 letter agreement.

NOW, THEREFORE, in consideration of the mutual promises and obligations contained herein and intending to be legally bound hereby, the Parties agree as follows:

1. The Parties acknowledge and agree that Employee’s last day as Chief Operating Officer (“COO”) of the Company shall be January 31, 2022 (the “COO Termination Date”). As of the COO Termination Date, Employee’s authority to act on behalf of the Company will end and he shall no longer report to the office, unless, upon reasonable notice, requested by the Chief Executive Officer or another senior executive. However, Employee shall be required to provide remote assistance on projects and transition of duties through December 31, 2022, unless earlier terminated by the Company under Paragraph 2(a)(i) or 2(a)(ii) or by Employee (the “Termination Date”). From the COO Termination Date until the Termination Date, Employee shall continue to receive the Base Salary that he received as of the COO Termination Date. Employee shall remain employed and a participant in all benefits plans until the Termination Date. The Parties further acknowledge and agree that the removal of Employee’s COO title shall be a Good Reason event for purposes of any outstanding equity awards and that such termination for Good Reason shall be deemed to take effect on the Termination Date.

2. In consideration of Employee executing this Agreement within a twenty-one day period immediately following receipt of this Agreement (and not revoking acceptance prior to the Release Effective Date, defined below) and Employee’s continued compliance with this Agreement, the Company agrees:

(a) To continue to employ and pay Employee’s Base Salary in effect at the COO Termination Date, in regular payroll installments, through the Termination Date, notwithstanding the removal of Employee’s regular duties; provided that the Company may immediately terminate Employee and cease paying the Base Salary if (i) Employee breaches this Agreement, including by failing to provide the remote assistance and cooperation to the Company described in Paragraph 1 herein, or (ii) Employee breaches either of Confidentiality and Noncompetition Agreement between Employee and the Company dated October 7, 2019 (the “Confidentiality Agreement”) or the Inventions and Intellectual Property Agreement between the Company dated October 7, 2019 (the “Inventions Agreement”).

3. Employee agrees and acknowledges that the payments provided for in Paragraph 2 exceed any payments to which he would otherwise be entitled under any policy, plan, and/or procedure of the Company or any agreement with the Company absent signing this Agreement. Employee agrees and acknowledges that he has received all payments and compensation to which he is entitled, and he is not owed any other money or compensation for work performed. Employee agrees and acknowledges that he shall not receive any bonus for 2022 or further equity not granted as of the Agreement Date. Employee agrees and acknowledges that no equity awards shall vest after the Termination Date.

4. Employee shall have up to twenty-one (21) days from the date of his receipt of this Agreement to consider the terms and conditions of this Agreement. Employee may accept this Agreement at any time within the twenty-one (21) day period by executing it and returning it to Lori Packer (lpacker@harvardbioscience.com) by email .pdf. Thereafter, Employee will have seven (7) days to revoke this Agreement by stating his desire to do so in writing (which may be by email) to Lori Packer (lpacker@harvardbioscience.com) no later than 5:00 p.m. on the seventh (7th) day following the date Employee signs this Agreement (as set forth below his signature). The effective date of this Agreement shall be the eighth (8th) day following Employee's signing of this Agreement (the "Release Effective Date"), provided the Employee does not revoke the Agreement during the revocation period. In the event Employee does not accept this Agreement as set forth above, or in the event Employee revokes this Agreement during the revocation period, this Agreement, including but not limited to the obligation of the Company and its subsidiaries and affiliates to provide the payments referred to in Section 2 above, shall automatically be deemed null and void.

5. (a) In consideration of the payments referred to in Section 2 above, Employee for himself and for his heirs, executors, and assigns (hereinafter collectively referred to as the "Releasors"), forever releases and discharges the Company and any and all of its parent corporations, subsidiaries, divisions, affiliated entities, predecessors, successors and assigns, and any and all of its and their employee benefit and/or pension plans and funds, and any and all of its and their past or present officers, directors, stockholders, partners, managers, members, agents, trustees, administrators, employees and assigns (whether acting as agents for such entities or in their individual capacities) (hereinafter collectively referred to as the "Releasees"), from any and all claims, demands, causes of action, fees and liabilities of any kind whatsoever (based upon any legal or equitable theory, whether contractual, common-law, statutory, decisional, federal, state, local or otherwise), whether known or unknown, which Releasors ever had, now have or may have against the Releasees or any of them by reason of any actual or alleged act, omission, transaction, practice, conduct, occurrence, or other matter from the beginning of the world to the date Employee signs this Agreement (as set forth below his signature).

(b) Without limiting the generality of the foregoing subsection (a), this Agreement is intended to and shall release the Releasees from any and all claims arising out of Employee's employment with Releasees and/or the termination of Employee's employment, including but not limited to: (i) any claims of discrimination or harassment in employment on the basis of age, religion, gender, sexual orientation, race, national origin, disability or any other legally protected characteristic, and of retaliation, under, without limitation, Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 1981, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the Equal Pay Act, and all other federal, state and local equal employment opportunity and fair employment practice laws (all as amended); (ii) any claims under the Employee Retirement Income Security Act of 1974 (except as set forth below), the Family and Medical Leave Act and state and local laws of similar effect, the National Labor Relations Act, Workers Adjustment and Retraining Notification Act, and other state and local laws of similar effect (all as amended); and (iii) any other claim (whether based on federal, state, or local law, statutory or decisional) relating to or arising out of Employee's employment, the terms and conditions of such employment, and/or the termination or separation of such employment, and/or any of the events and decisions relating directly or indirectly to or surrounding the termination of that employment, including but not limited to claims for breach of contract (express or implied), wrongful discharge, detrimental reliance, defamation, whistleblowing, harassment, retaliation, mental distress, emotional distress, physical injury, humiliation or compensatory or punitive damages.

(c) Notwithstanding the foregoing, nothing in this Agreement shall be construed to prevent Employee from filing a charge with or participating in an investigation conducted by any governmental agency, including, without limitation, the United States Equal Employment Opportunity Commission ("EEOC") or applicable state or city fair employment practices agency or the Securities and Exchange Commission ("SEC"), to the extent required or permitted by law. Nevertheless, Employee understands and agrees that he is waiving any relief available (including, for example, monetary damages or reinstatement), under any of the claims and/or causes of action waived in Sections 5(a) and (b), including but not limited to financial benefit or monetary recovery from any lawsuit filed or settlement reached by the EEOC with respect to any claims released and waived in this Agreement.

(d) Nothing in this Agreement shall be construed to waive, release or discharge any rights that Employee has to corporate indemnification or insurance coverage by the Company or its insurers.

6. (a) Employee agrees that, upon the execution of this Agreement by the parties and upon the Release Effective Date of this Agreement, he has no claims against the Company and is not aware of any unlawful conduct by the Company. Employee agrees that he will not disparage (or induce or encourage others to disparage) the Company or the Releasees. The Company agrees that it will not publicly disparage (or induce or encourage others to publicly disparage) Employee. For purposes of the preceding sentence only, the Company shall mean Employee officers or directors of the Company. The Parties further agree that all reference inquiries regarding Employee and his employment shall be referred to Human Resources, who shall provide only dates of employment.

(b) Employee acknowledges that he has returned to the Company, or at the Company's election destroyed, any and all originals and copies of documents, materials, records, credit cards, keys, building passes, computers, cell phones and other electronic devices or other items in his possession or control belonging to the Company or containing confidential information relating to the Company. Employee acknowledges that he has received all personal property from the Company and no such property contains confidential information.

7. The terms and conditions of this Agreement are and shall be deemed to be confidential and shall not be disclosed by Employee to any person or entity without the prior written consent of the Company, and to Employee's accountants or tax preparers, attorneys, and licensed financial advisors provided that they agree to maintain the confidentiality of this Agreement. Employee further represents that he has not disclosed the terms and conditions of this Agreement to anyone other than to the aforementioned persons. Employees acknowledges and agrees that the Confidentiality Agreement and the Inventions Agreement remain in full force and effect on their terms.

8. The making of this Agreement is not intended, and shall not be construed, as an admission that the Releasees have violated any federal, state or local law (statutory or decisional), ordinance or regulation, breached any contract, or committed any wrong whatsoever against Employee. The parties agree that this Agreement may not be used as evidence in a subsequent proceeding except in a proceeding to enforce the terms of this Agreement.

9. Employee acknowledges that: (a) he has carefully read this Agreement in its entirety; (b) he has had an opportunity to consider fully the terms of this Agreement and been given twenty-one (21) days to consider its terms; (c) he has been advised by the Company in writing to consult with an attorney of his choosing in connection with this Agreement; (d) he fully understands the significance of all of the terms and conditions of this Agreement and he has discussed it with his independent legal counsel, or has had a reasonable opportunity to do so; (e) he has had answered to his satisfaction any questions he has asked with regard to the meaning and significance of any of the provisions of this Agreement; and (f) he is signing this Agreement voluntarily and of his own free will and assents to all the terms and conditions contained herein.

10. This Agreement is binding upon, and shall inure to the benefit of, the parties and their respective heirs, executors, administrators, successors and assigns.

11. If any provision of this Agreement shall be held by a court of competent jurisdiction to be illegal, void, or unenforceable, such provision shall be of no force and effect. However, the illegality or unenforceability of such provision shall have no effect upon, and shall not impair the enforceability of, any other provision of this Agreement; provided, however, that, upon any finding by a court of competent jurisdiction that any of the release or covenants provided for by Section 5, 6, and/or 7 above is illegal, void, or unenforceable, Employee agrees to execute a release, waiver and/or covenant with substantially similar provisions that is legal and enforceable. Any breach of Sections 5, 6, and/or 7 above by Employee shall constitute a material breach of this Agreement as to which the Company may seek appropriate relief and shall entitle Company to cease continuing payments under Section 2.

12. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Minnesota, without regard to the conflict of laws provisions thereof. Actions to enforce the terms of this Agreement, or that relate to Employee's employment with the Company shall be submitted to the exclusive jurisdiction of any state or federal court sitting in Minnesota.

13. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party. Facsimile or .pdf signatures shall have the same force and effect as original signatures.

14. This Agreement constitutes the complete understanding between the parties with respect to the separation of Employee's employment at the Company and supersedes any and all agreements, understandings, and discussions, whether written or oral, between the parties. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by each of the parties hereto.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the 26th day of January, 2022.

Ken Olson

Harvard Bioscience, Inc.

/s/ Ken Olson

/s/ Michael A. Rossi

Signature of Employee

Signature of Authorized Representative

January 27, 2022

January 26, 2022

Date

Date